在中国为医院表单决策提供信息:GLP-1受体激动剂的多标准价值框架
Yuancheng Jiang1, Dan Qin2, Sitong Lin1
1Department of Pharmacy Management, College of International Pharmaceutical Business School, China Pharmaceutical University, Nanjing, People's Republic of China.
Risk management and healthcare policy
|February 27, 2026
概括
一个新的评估系统有助于医院选择葡萄糖类-1 (GLP-1) 受体激动剂的药物. 该框架支持合理选择,以更好地控制血糖和体重,改善医疗保健决策.
科学领域:
- 药物经济学 药物经济学
- 医疗保健服务研究 医疗服务研究
- 临床药房 临床药房
背景情况:
- 葡萄糖类-1 (GLP-1) 受体激动剂为血糖控制和减肥提供了双重好处.
- 尽管它被列入中国国家补偿药物清单,但GLP-1受体激动剂的医院级采用面临挑战.
- 结构化的评估框架对于将这些药物整合到医院配方中至关重要.
研究的目的:
- 在公共医院药物选择中开发GLP-1受体激动剂的综合临床评估系统.
- 为合理选择和实施GLP-1受体激动剂 (GLP-1RAs) 提供系统和可量化的工具.
- 加强医院关于GLP-1RAs的表单决策的科学基础.
主要方法:
- 整合了德尔菲方法和多标准决策分析 (MCDA).
- 利用文献审查,专家咨询和问卷调查来选择和加权指标.
- 开发了一个三级评估系统,包括初级,二级和三级指标.
主要成果:
- 建立了一个由4个初级,8个二级和17个三级指标组成的三层系统.
- "临床价值" (0.5373) 获得了最高的权重,其次是"入院需求" (0.1924) 和"医院管理" (0.1379).
- 影响决策的关键三级指标包括"成本效益优势"",糖化血红蛋白"",心血管,肝脏和脏益处"",解决未满足的临床需求"和"低血糖发生率".
结论:
- 这项研究解决了中国GLP-1RAs临床评估研究中的差距.
- 拟议的评估系统为医院药品管理,医疗保险和药物采购提供科学支持.
- 促进基于价值的GLP-1受体激动剂医院药物选择策略.
相关概念视频
Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
54
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
54
G Protein-coupled Receptors
18.3K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
18.3K
Drug Products: Biologics, Biosimilars and Interchangeables
311
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
311
Clinically Relevant Drug Product Specifications: Methods of Establishment
275
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
275
Dosage Regimen: Individualization
232
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
232

